Drug Profile
Research programme: antibacterials - BioRelix/Dalton Medicinal Chemistry
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator BioRelix; Dalton Medicinal Chemistry
- Class
- Mechanism of Action RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in Canada
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA
- 06 Oct 2010 Preclinical development is ongoing in the US and Canada